

PRESS RELEASE
22 January 2015



BioInvent appoints head of clinical development

Lund, Sweden – 22 January, 2015 – BioInvent International AB (OMXS: BINV) today announced that Anna Wickenberg has been appointed as Vice President Clinical Development, responsible for the clinical development of BioInvent's drug development projects. She will be part of the Management group and reports to the CEO.

Anna Wickenberg (born 1974) holds PhD in Medical Sciences, Immunology, and a MSc in Molecular Biology. She has 15 years of experience of leading clinical development projects from various positions at Teva Pharmaceuticals, NeuroSearch, and AstraZeneca. Most recently, Anna was responsible for the clinical development of new chemical entities in an orphan indication within CNS at Teva.

"Several of BioInvent's drug development projects have reached a point that makes it necessary to strengthen the company's expertise in clinical development. We are therefore pleased to welcome Anna Wickenberg, who will bring deep knowledge and long experience within this area." **says Michael Oredsson, CEO of BioInvent.**

To the editors:

About BioInvent

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR[®] are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of new drugs, and provide BioInvent with the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, and Xoma. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 18 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com